Vertically integrated medical cannabis leader with operations in Europe and Latin America, Khiron Life Sciences Corp (OTCMKTS:KHRNF) on October 1, 2021, announced that Joel Friedman resigned as the Chief Financial Officer due to personal reasons. The company’s board of directors has appointed SwapanKakumanu of RTB LLP as Interim CFO. Friedman would continue with Khirontill October 31, 2021, for providing transitional support.
Mr. Alvaro Torres, Khiron CEO and Director expressed gratitude to Joel for the contributions as well as leadership to the firm’s robust finance team and wished the best for future endeavors.
The interim CFO, Kakumanu has over 25 years of experience in finance and operations serving at senior executive management both in private and public companies functioning in manufacturing, technology, blockchain as well as oil field services industries. His organization RTB LLP has accounting professionals having extensive industry experience. Kakumanu has also held senior roles as President, CEO, CFO as well as Board Member for public and private companies.
Khiron Life Sciences Corp has wholly-owned medical health centers as well as proprietary telemedicine platforms. The firm combines a patient-oriented approach, scientific expertise, physician education programs as well as product innovation to drive prescriptions. With a presence in Colombia, Peru, Germany, UK, and Brazil, the firm will also commence sales in Mexico in 2021.
On Friday, KHRNF stock fell 1.77% at $0.2160 with more than 186k shares, compared to its average volume of 352K shares. The stock has moved within a range of $0.2102 – 0.2260 after opening the trade at $0.21.